vs

Side-by-side financial comparison of Phathom Pharmaceuticals, Inc. (PHAT) and TXO Partners, L.P. (TXO). Click either name above to swap in a different company.

TXO Partners, L.P. is the larger business by last-quarter revenue ($103.7M vs $57.6M, roughly 1.8× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 14.5%).

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

TXO Partners, L.P. is a U.S.-based energy sector master limited partnership. It acquires, develops and manages oil and natural gas assets across key North American production basins, with operations covering upstream exploration, production and midstream transportation, serving industrial, utility and wholesale energy clients.

PHAT vs TXO — Head-to-Head

Bigger by revenue
TXO
TXO
1.8× larger
TXO
$103.7M
$57.6M
PHAT
Growing faster (revenue YoY)
PHAT
PHAT
+79.7% gap
PHAT
94.1%
14.5%
TXO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PHAT
PHAT
TXO
TXO
Revenue
$57.6M
$103.7M
Net Profit
$-28.3M
Gross Margin
86.7%
Operating Margin
-26.1%
Net Margin
-27.2%
Revenue YoY
94.1%
14.5%
Net Profit YoY
71.6%
-376.5%
EPS (diluted)
$-0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PHAT
PHAT
TXO
TXO
Q4 25
$57.6M
$103.7M
Q3 25
$49.5M
$90.6M
Q2 25
$39.5M
$75.0M
Q1 25
$28.5M
$93.8M
Q4 24
$29.7M
$90.6M
Q3 24
$16.4M
$69.3M
Q2 24
$7.3M
$57.0M
Q1 24
$68.5M
Net Profit
PHAT
PHAT
TXO
TXO
Q4 25
$-28.3M
Q3 25
$-30.0M
$4.4M
Q2 25
$-75.8M
$-135.0K
Q1 25
$-94.3M
$2.4M
Q4 24
$10.2M
Q3 24
$-85.6M
$203.0K
Q2 24
$-91.4M
$2.8M
Q1 24
$10.3M
Gross Margin
PHAT
PHAT
TXO
TXO
Q4 25
86.7%
Q3 25
87.5%
Q2 25
87.2%
Q1 25
86.9%
Q4 24
87.1%
Q3 24
85.6%
Q2 24
81.2%
Q1 24
Operating Margin
PHAT
PHAT
TXO
TXO
Q4 25
-26.1%
Q3 25
-30.8%
4.2%
Q2 25
-151.7%
-5.0%
Q1 25
-276.5%
-3.8%
Q4 24
6.1%
Q3 24
-433.0%
-7.2%
Q2 24
-1055.4%
-17.7%
Q1 24
3.9%
Net Margin
PHAT
PHAT
TXO
TXO
Q4 25
-27.2%
Q3 25
-60.5%
4.8%
Q2 25
-191.9%
-0.2%
Q1 25
-330.7%
2.6%
Q4 24
11.3%
Q3 24
-523.3%
0.3%
Q2 24
-1248.6%
4.9%
Q1 24
15.0%
EPS (diluted)
PHAT
PHAT
TXO
TXO
Q4 25
$-0.57
Q3 25
$-0.41
$0.08
Q2 25
$-1.05
$0.00
Q1 25
$-1.31
$0.06
Q4 24
$0.22
Q3 24
$-1.32
$0.01
Q2 24
$-1.56
$0.09
Q1 24
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PHAT
PHAT
TXO
TXO
Cash + ST InvestmentsLiquidity on hand
$130.0M
$9.4M
Total DebtLower is stronger
$209.1M
$291.1M
Stockholders' EquityBook value
$-438.2M
Total Assets
$259.1M
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PHAT
PHAT
TXO
TXO
Q4 25
$130.0M
$9.4M
Q3 25
$135.2M
$5.3M
Q2 25
$149.6M
$8.0M
Q1 25
$212.3M
$10.8M
Q4 24
$297.3M
$7.3M
Q3 24
$334.7M
$3.8M
Q2 24
$276.2M
$76.0M
Q1 24
$4.6M
Total Debt
PHAT
PHAT
TXO
TXO
Q4 25
$209.1M
$291.1M
Q3 25
$207.1M
$271.1M
Q2 25
$205.1M
$19.1M
Q1 25
$203.2M
$162.1M
Q4 24
$201.4M
$157.1M
Q3 24
$175.7M
$155.1M
Q2 24
$174.4M
$7.1M
Q1 24
$26.1M
Stockholders' Equity
PHAT
PHAT
TXO
TXO
Q4 25
$-438.2M
Q3 25
$-422.5M
Q2 25
$-405.8M
Q1 25
$-338.4M
Q4 24
$-253.6M
Q3 24
$-187.1M
Q2 24
$-233.8M
Q1 24
Total Assets
PHAT
PHAT
TXO
TXO
Q4 25
$259.1M
$1.4B
Q3 25
$240.3M
$1.4B
Q2 25
$250.2M
$1.0B
Q1 25
$294.2M
$1.0B
Q4 24
$378.3M
$1.0B
Q3 24
$387.0M
$1.0B
Q2 24
$319.4M
$774.5M
Q1 24
$688.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PHAT
PHAT
TXO
TXO
Operating Cash FlowLast quarter
$-166.8M
$32.5M
Free Cash FlowOCF − Capex
$-167.0M
FCF MarginFCF / Revenue
-290.0%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-328.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PHAT
PHAT
TXO
TXO
Q4 25
$-166.8M
$32.5M
Q3 25
$-14.1M
$28.3M
Q2 25
$-62.7M
$26.9M
Q1 25
$-84.9M
$30.6M
Q4 24
$-266.8M
$40.5M
Q3 24
$-63.6M
$20.7M
Q2 24
$-70.7M
$22.9M
Q1 24
$25.2M
Free Cash Flow
PHAT
PHAT
TXO
TXO
Q4 25
$-167.0M
Q3 25
$-14.1M
Q2 25
$-62.8M
Q1 25
$-84.9M
Q4 24
$-266.9M
Q3 24
$-63.6M
Q2 24
$-70.8M
Q1 24
FCF Margin
PHAT
PHAT
TXO
TXO
Q4 25
-290.0%
Q3 25
-28.6%
Q2 25
-159.0%
Q1 25
-297.9%
Q4 24
-899.8%
Q3 24
-389.0%
Q2 24
-966.2%
Q1 24
Capex Intensity
PHAT
PHAT
TXO
TXO
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.2%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.3%
Q2 24
0.6%
Q1 24
Cash Conversion
PHAT
PHAT
TXO
TXO
Q4 25
Q3 25
6.50×
Q2 25
Q1 25
12.67×
Q4 24
3.96×
Q3 24
102.02×
Q2 24
8.15×
Q1 24
2.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PHAT
PHAT

Segment breakdown not available.

TXO
TXO

Oil And Condensate$92.8M89%
Natural Gas Liquids Reserves$8.2M8%
Other$2.8M3%

Related Comparisons